BMJ: United States’ FDA providing insufficient information on post-approval drug effectiveness.
May 23, 2018
Bill Thompson
May 29, 2018
Class Action, Daily, Government, Health, Pharma, Products, Quality Fraud, Science, Statistics
Comments Off on May 23, 2018